David Templeton
Fortuna: - $ al 31/05/2026
Fortuna: - $ al 31/05/2026
Dr. David Templeton was previously employed as an Executive Director & Technical Director by N4 Pharma Plc, a Director-Clinical Pharmacology by Eisai Ltd. (United Kingdom), a Head-Non Clinical Development by Celltech Ltd., and a Head-Biometrics by Merck Generics Ltd.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/12/2024 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| THALIA THERAPEUTICS PLC | Presidente | 21/05/2019 |
Eisai Ltd. (United Kingdom)
Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | 01/01/2010 |
Celltech Ltd.
Celltech Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural science and engineering | Corporate Officer/Principal | 01/01/2004 |
Merck Generics Ltd.
Merck Generics Ltd. Pharmaceuticals: MajorHealth Technology Provides therapies and drugs products | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Eisai Ltd. (United Kingdom)
Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Celltech Ltd.
Celltech Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural science and engineering | Commercial Services |
N4 Pharma Plc
N4 Pharma Plc BiotechnologyHealth Technology Provides specialist pharmaceutical services that reformulates existing drugs and vaccines to improve their performance | Health Technology |
Merck Generics Ltd.
Merck Generics Ltd. Pharmaceuticals: MajorHealth Technology Provides therapies and drugs products | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.